company-header-background

Clinical

Manufacturing

Must provide “substantial evidence” of product’s safety and efficacy in humans.
Clinical Studies are Grouped into Three Phases:
The first step is to file an Investigational New Drug (IND) application which is supported by the data from the Pre-Clinical Phase. Studies performed under an IND are often classified into phases as if they are separate and distinct steps in the process. In reality, the phases overlap and trials in one phase are often conducted simultaneously with trials in other phases. Clinical studies are grouped according to their objective into three types or phases:

 

Phase I Clinical Development (Human Pharmacology) – Thirty days after a biopharmaceutical company has filed its IND, it may begin a small-scale Phase I clinical trial unless the FDA places a hold on the study. Phase I studies are used to evaluate pharmacokinetic parameters and tolerance, generally in healthy volunteers.  These studies include initial single-dose studies, dose escalation, and short-term repeated-dose studies.

Phase II Clinical Development (Therapeutic Exploratory) – Phase II clinical studies are small-scale trials to evaluate a drug’s preliminary efficacy and side-effect profile in 100 to 250 patients.  Additional safety and clinical pharmacology studies are also included in this category.

Phase III Clinical Development (Therapeutic Confirmatory) – Phase III studies are large-scale clinical trials for safety and efficacy in large patient populations. While phase III studies are in progress, preparations are made for submitting the Biologics License Application (BLA) or the New Drug Application (NDA).  BLAs are currently reviewed by the FDA’s Center for Biologics Evaluation and Research (CBER).  NDAs are reviewed by the Center for Drug Evaluation and Research (CDER).

 

The biological activity of nanoparticles can be influenced by the manufacturing process.


Clinical Manufacturing Solutions

Scalable manufacturing is a significant challenge to making revolutionary nanomedicines available to patients in need. PNI’s Clinical Solutions Team provides a complete clinical manufacturing solution for nanomedicines. Our Scale-Up System technology is modular, customizable and services include analytical services and CMC support. Additionally, our expertise and services include license & supply agreements, site audits, and CMO partnerships. Precision NanoSystems provides complementary technology and over 100 years of combined scientific expertise.


Scale-Up System

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch

Resource Center

Poster

July 01, 2018

Robust low-volume production of nanoparticles for genetic manipulation of cells

Read More PDF

Application Note

July 01, 2018

Seamless scale up of liposomal verteporfin formulations using the NanoAssemblr® Platform

Read More PDF

Publication - Abstract

April 26, 2018

Small Methods

State‐of‐the‐Art Design and Rapid‐Mixing Production Techniques of Lipid Nanoparticles for Nucleic Acid Delivery

Evers, M. J. W., Kulkarni, J. A., van der Meel, R., Cullis, P. R., Vader, P., & Schiffelers, R. M.

Read More

Publication - Abstract

February 27, 2018

Cell Reports

A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing

J. Finn, A. Smith, M. Patel, L. Shaw, M. Youniss, J. Heteren, T. Dirstine, C. Ciullo, R. Lescarbeau, J. Seitzer, R. Shah...

Read More

Video

September 14, 2018

From Concept to Reality: Development of Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics - Martin Maier, Alnylam

Read More

Poster

August 04, 2018

Microfluidic Manufacture of PLGA Nano and Microparticle Drug Delivery Vehicles

Read More PDF
Resource Center

Stay Informed

Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.

MENU
X